Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
Skyline Medical said yesterday it inked a merger transaction deal with privately held biomedical firm CytoBioscience.
San Antonio, Texas-based CytoBioscience develops and produces devices used in human cell research and drug development, Skyline Medical said, and has collaborative partnerships with pharmaceutical companies and academic institutions. Read more
Shares in Dexcom rose today after the diabetes-focused medical device maker topped expectations on Wall Street with its 2nd quarter earnings results and announced a new chief financial officer.
The San Diego, Calif.-based company posted profits of $2.9 million, or 3¢ per share, on sales of $170.6 million for the 3 months ended June 30, seeing the bottom-line swing from losses of $20.2 million while sales grew 24.3% compared with the same period during the previous year. Read more
In the drive toward tinier implantable medical devices and wearable health sensors, battery and power source technology has been a major stumbling block.
As experts noted in a discussion about battery technology during DeviceTalks Minnesota in June, battery innovation in the field is especially slow. Going too fast has its risks, too. Case in point is the literally explosive history of rechargeable lithium ion batteries. Read more
Shares in Cardinal Health fell today after the medical device maker posted a 17.7% drop in profits in its 4th quarter and 9.6% drop for its fiscal year 2017 earnings results, despite topping expectations on Wall Street.
The Dublin, Ohio-based company posted profits of $274 million, or 86¢ per share, on sales of $33 billion for the 3 months ended June 30, seeing profits shrink 17.7% while sales grew 5.1% compared with the same period in the previous year. Read more
Medtronic said today it won CE Mark approval in the European Union and FDA approval in the US for its Avalus pericardial aortic surgical valve designed to treat aortic valve disease.
The Avalus is the Fridley, Minn.-based company’s next-gen pericardial surgical aortic valve, and features a supra-annular design to improve hemodynamic performance and limit central regurgitation. Read more